Oncogenex Cancels IPO

Oncogenex Technologies Inc., a Vancouver-based drug company focused on cancer therapeutics, has canceled its proposed IPO due to “current market conditions.” The company had been planning to raise up to $37.5 million based on amended terms. It originally planned to raise up to $54 million. RBC Capital Markets was serving as lead underwriter. Shareholders include Ventures West, BDC Venture Capital, GrowthWorks, HIG Capital and Milestone Medica Corp. www.oncogenex.ca